Literature DB >> 35188627

PBPK Modeling to Simulate the Fate of Compounds in Living Organisms.

Frédéric Y Bois1, Cleo Tebby2, Céline Brochot2.   

Abstract

Pharmacokinetics study the fate of xenobiotics in a living organism. Physiologically based pharmacokinetic (PBPK) models provide realistic descriptions of xenobiotics' absorption, distribution, metabolism, and excretion processes. They model the body as a set of homogeneous compartments representing organs, and their parameters refer to anatomical, physiological, biochemical, and physicochemical entities. They offer a quantitative mechanistic framework to understand and simulate the time-course of the concentration of a substance in various organs and body fluids. These models are well suited for performing extrapolations inherent to toxicology and pharmacology (e.g., between species or doses) and for integrating data obtained from various sources (e.g., in vitro or in vivo experiments, structure-activity models). In this chapter, we describe the practical development and basic use of a PBPK model from model building to model simulations, through implementation with an easily accessible free software.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  1,3-Butadiene; Monte Carlo simulations; Numerical integration; PBPK; R software

Mesh:

Substances:

Year:  2022        PMID: 35188627     DOI: 10.1007/978-1-0716-1960-5_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  49 in total

1.  Quantitative structure-pharmacokinetics relationships: II. A mechanistically based model to evaluate the relationship between tissue distribution parameters and compound lipophilicity.

Authors:  I Nestorov; L Aarons; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-10

2.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.

Authors:  Harvey J Clewell; P Robinan Gentry; Tammie R Covington; Ramesh Sarangapani; Justin G Teeguarden
Journal:  Toxicol Sci       Date:  2004-03-31       Impact factor: 4.849

Review 3.  Physiologically-based pharmacokinetics in drug development and regulatory science.

Authors:  Malcolm Rowland; Carl Peck; Geoffrey Tucker
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

4.  A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals.

Authors:  Thomas Peyret; Patrick Poulin; Kannan Krishnan
Journal:  Toxicol Appl Pharmacol       Date:  2010-09-30       Impact factor: 4.219

5.  A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan.

Authors:  Rémy Beaudouin; Sandrine Micallef; Céline Brochot
Journal:  Regul Toxicol Pharmacol       Date:  2010-02-01       Impact factor: 3.271

6.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

7.  Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model.

Authors:  R J Lutz; R L Dedrick; D Tuey; I G Sipes; M W Anderson; H B Matthews
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

Review 8.  Physiologically based pharmacokinetic modeling: principles and applications.

Authors:  L E Gerlowski; R K Jain
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

9.  Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species.

Authors:  R L Dedrick; D D Forrester; J N Cannon; S M el-Dareer; L B Mellett
Journal:  Biochem Pharmacol       Date:  1973-10-01       Impact factor: 5.858

10.  Human styrene exposure. V. Development of a model for biological monitoring.

Authors:  P O Droz; M P Guillemin
Journal:  Int Arch Occup Environ Health       Date:  1983       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.